Subject:  Re: ANTHRAX ALERT...This Will Be Huge! |
Author:
Burt
|
[
Next Thread |
Previous Thread |
Next Message |
Previous Message
]
Date Posted: 18:56:22 04/08/05 Fri
In reply to:
JoeKernanCNBC
's message, "ANTHRAX ALERT...This Will Be Huge!" on 02:37:40 03/31/05 Thu
this stock is up topday
http://www.google.com/search?hl=en&lr=&q=AVN&btnG=Search
>ANTHRAX ALERT...This Will Be Huge!
>
>Get in on the ground floor while the stock is still
>cheap! For more
>info got to http://www.avanir.com
>
>AVANIR's Anthrax Antibody Data Presented at 2005 ASM
>Biodefense
>Research Meeting
>
>
>
>SAN DIEGO--(BUSINESS WIRE--AVANIR Pharmaceuticals'
>(AMEX:AVN - News)
>anti-anthrax monoclonal antibodies have demonstrated
>an ability to
>protect against the most lethal form of anthrax toxins
>in animal
>models. Data from additional studies conducted by
>Johnny W.
>Peterson, Ph.D., of the University of Texas Medical
>Branch were
>presented today in a poster entitled "Human Monoclonal
>Antibodies to
>Protective Antigen with and without Ciprofloxacin
>Protect Mice and
>Guinea Pigs against Inhalation Anthrax" at the 2005
>American Society
>for Microbiology (ASM) Biodefense Research Meeting
>being held this
>week in Baltimore, Maryland.
>
>
>
>"Human anti-PA monoclonal antibodies supplied by AVANIR
>Pharmaceuticals have been shown to protect against
>lethal infection
>in mice and guinea pigs challenged with B. anthracis
>spores
>instilled into the respiratory tract," said Dr.
>Peterson. "Our
>research indicates delay in death and survival is
>significantly
>increased by co-administration of antibodies with low
>levels of
>ciprofloxacin."
>
>The in vivo tests on passive immunization with AVANIR
>human
>monoclonal antibodies are being conducted in small
>animal models
>established at the University of Texas Medical Branch
>in Galveston
>under contract from the National Institute of Allergy
>and Infectious
>Disease (NIAID), a division of the National Institutes
>of
>Health. "AVANIR's human monoclonal antibodies to
>protective antigen
>(PA), such as AVP-21D9, have high specificity and very
>desirable
>binding properties, and offer considerable promise for
>the rapid
>development of products useful as adjuncts to current
>antimicrobial
>prophylaxis and therapy against inhalation anthrax,"
>continued Dr.
>Peterson.
>
>Antibodies that neutralize anthrax toxins may augment
>existing
>treatment options. Currently, a vaccine and
>antibiotics are the
>treatment options available for the prevention or
>treatment of
>anthrax exposure. Both approaches have limitations.
>The anthrax
>vaccine takes weeks following the first doses before
>immunity is
>established, and requires multiple injections over a
>period of
>months, in addition to annual boosters, to reach and
>maintain its
>protective effect. Antibiotics, the standard treatment
>of anthrax
>infection, are effective in killing anthrax bacteria,
>but have no
>effect on the anthrax toxins.
>
>"These data indicate that AVP-21D9 may provide the
>necessary
>immediate protection before other treatment regimens
>take effect,"
>concluded Dr. Peterson.
>
>AVANIR Pharmaceuticals is a drug discovery and
>development company
>focused on treatments for chronic diseases. Our
>product candidates
>address therapeutic markets that include central
>nervous system and
>cardiovascular disorders, inflammation, and infectious
>disease. The
>Company's first commercialized product, AbrevaŽ, is
>marketed in
>North America by GlaxoSmithKline Consumer Healthcare
>and is the
>leading over-the-counter product for the treatment of
>cold sores.
>Further information about AVANIR can be found at
>www.avanir.com.
[
Next Thread |
Previous Thread |
Next Message |
Previous Message
]
| |
Feedback: 